Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Viking Therapeutics shows promise with their VK2735 drug demonstrating significant weight loss in Phase 2 trials. Despite strong data, Viking faces intense competition and strategic challenges in a ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $33.54, denoting a -3.44% move from the preceding trading day.

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best healthcare stocks with the highest upside. Viking Therapeutics, ...

Deep-pocketed investors have adopted a bullish approach towards Viking Therapeutics (NASDAQ:VKTX), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...

Explore the exciting world of Viking Holdings (NYSE: VIK) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...

Viking’s newly announced 2027-28 deployment includes six ships operating winter itineraries in Europe. Nearly half of the ...